Safety and efficacy of ketamine-augmented electroconvulsive therapy in third trimester pregnancy complicated by COVID-19

Ashmi Patel, Anna Claire Saucier, Christopher Hobday, Ranjit Chacko

Research output: Contribution to journalArticlepeer-review

Abstract

Major depressive disorder during pregnancy can be detrimental to the fetus and patient. Treatments can include electroconvulsive therapy (ECT) for severe cases. The use of ketamine in ECT can provide symptomatic relief as well as induce anesthesia. Here, we describe the case of a 35-year-old gravid woman with a long-standing history of major depressive disorder who presented with treatment-resistant depression with suicidal ideation after an alteration in her antidepressant medication. After psychiatric evaluation, she was deemed to be a good candidate for ECT augmented with ketamine for symptomatic relief. This was complicated by an positive but asymptomatic COVID-19 status. Despite these factors, the patient experienced significant relief after an eight-treatment course of ECT, with a reduction of her PHQ-9 score from 22/27 to 4/27 points.

Original languageEnglish (US)
JournalBaylor University Medical Center Proceedings
DOIs
StateAccepted/In press - 2022

Keywords

  • Electroconvulsive therapy
  • high-risk pregnancy
  • ketamine
  • major depression
  • suicidal ideation
  • treatment-resistant depression

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Safety and efficacy of ketamine-augmented electroconvulsive therapy in third trimester pregnancy complicated by COVID-19'. Together they form a unique fingerprint.

Cite this